肿瘤嗜器官性转移的双向选择与共同适应机制

王星, 肖枘伶, 白嘉璐, 蒋德诚, 周飞晗, 罗稀元, 唐玥萌, 赵玉沛

  1. 1.中国医学科学院北京协和医院基本外科,北京 100023
    2.中国医学科学院胰腺肿瘤重点实验室,北京 100023
    3.中国医学科学院北京协和医院转化医学国家重大科技基础设施,北京 100023
    4.中国医学科学院北京协和医院疑难重症及罕见病全国重点实验室,北京 100730
  • 收稿日期:2024-11-21 修回日期:2025-01-25 出版日期:2025-05-30 发布日期:2025-06-10
  • 通信作者: 赵玉沛
  • 作者简介:王星(ORCID: 0000-0002-0804-2956),博士在读。
  • 基金资助:
    中央高水平医院临床科研专项(2022-PUMCH-D-001);中国医学科学院医学科学创新基金(2023-I2M-2-002)

摘要/Abstract

摘要:

肿瘤转移是恶性肿瘤进展过程中最为复杂且影响深远的环节,通常与患者的预后密切相关。约90%的肿瘤相关死亡均与转移有关,且合并转移的实体瘤患者的5年生存率仅为5%~30%。因此,深入理解肿瘤转移的生物学机制,对于揭示肿瘤转移现象的本质并确立新的治疗策略具有重要意义。肿瘤转移的发生需要肿瘤细胞跨越多个生物学屏障,包括脱离原发部位、侵入血管或淋巴管、在血液循环中存活、侵犯远处器官并适应局部环境等多个步骤。为了克服这些挑战,肿瘤细胞必须经历一系列表型转变、基因突变及细胞信号转导通路的异常激活。此外,微环境因素(如血管生成、基质重塑、免疫逃逸等)也在转移过程中发挥关键作用。这些因素相互促进、共同推动了转移灶的形成和生长。嗜器官性转移是肿瘤转移的一种特殊形式。肿瘤细胞与靶器官微环境之间的双向选择与适应性演变,构成了嗜器官性转移的核心驱动因素,涉及细胞-细胞、细胞-基质等多层次的相互作用。具体而言,原位肿瘤的突变位点、信号分子的释放、克服循环压力的能力及与靶器官的信号交流等因素共同调控了嗜器官性转移的选择性。与此同时,靶器官的再生能力、代谢特征、免疫监视机制及基质硬度等因素又进一步促进了转移瘤到达靶器官后的适应性重塑。因此,肿瘤细胞与靶器官之间的双向选择、适应过程构成了一个复杂的动态系统,这为我们理解转移性肿瘤的形成和发展提供了新的视角。目前的研究大多集中在肿瘤转移过程中一些共性生物学特征上。然而,转移性肿瘤的形成不仅依赖于这些共性机制,还与嗜器官性转移的特性密切相关。共性与特性之间的对立统一关系深刻影响着肿瘤转移的最终结果。为此,本文将概述肿瘤转移进程中共性的生物学特征,重点介绍当前对转移瘤和靶器官的双向选择、适应演变机制的认识,最后总结未发生转移的患者转移风险预测模型的构建现状及在合并转移的晚期肿瘤患者综合管理中面临的挑战和机遇,旨在为揭示肿瘤转移的本质、优化临床治疗策略及改善患者预后提供新的理论支持和实践指导。

关键词: 恶性肿瘤, 嗜器官性转移, 双向选择, 共同适应, 精准治疗

Abstract:

Metastasis is a pivotal and intricate process in the progression of malignant tumors, strongly correlating with poor prognosis. Approximately 90% of cancer-related mortality is attributed to metastasis, with the five-year survival rate for patients with metastatic solid tumors ranging from 5% to 30%. Consequently, a comprehensive understanding of the underlying biological mechanisms driving metastasis is essential for unraveling its core processes and developing novel therapeutic strategies. The metastatic cascade involves tumor cells navigating numerous biological barriers, including detachment from the primary tumor, invasion of blood vessels or lymphatics, survival in circulation, extravasation into distant organs and subsequent adaptation to the microenvironment. To surmount these challenges, tumor cells undergo phenotypic changes, genetic mutations and dysregulating signaling pathways. Additionally, microenvironmental factors (such as angiogenesis, matrix remodeling and immune evasion) play a critical role, orchestrating the initiation and growth of metastatic lesions in an interdependent manner. Organ-specific metastasis, a distinct subset of metastasis, involves dynamic bidirectional interactions between tumor cells and the microenvironment of target organs. These interactions determine the selectivity of metastatic spread and drive the adaptive evolution of both the tumor and the organ, which encompasses multiple layers of cellular interactions, including cell-cell and cell-matrix signaling. Tumor cell mutations, the release of specific signaling molecules, the capacity to withstand circulatory pressures, and signaling exchanges with target organs collectively govern the selective nature of organ-specific metastasis. Furthermore, factors intrinsic to the target organ-such as its regenerative potential, metabolic profile, immune surveillance mechanisms and matrix stiffness-further facilitate the adaptive remodeling of metastatic cells within these environments. Thus, the bidirectional selection and adaptation between tumor cells and target organs form a dynamic, complex system that reshapes our understanding of metastatic tumor development. While current research emphasizes shared biological features in metastasis, the successful formation of metastatic tumors depends not only on these common mechanisms but also on the unique characteristics governing organ-specific metastasis. The interplay between generalizable and organ-specific mechanisms profoundly influences the metastatic outcome. This review aimed to consolidate our current knowledge of these shared and distinct processes, analyze the evolving understanding of the bidirectional selection between tumor cells and target organs, and assess the current status of metastatic risk prediction models for patients without metastasis. Furthermore, the paper discussed the challenges and opportunities in managing advanced-stage metastatic tumors, offering new insights and potential clinical strategies to improve prognosis and treatment outcomes.

Key words: Malignant neoplasms, Organotropic metastasis, Bidirectional selection, Mutual adaptation, Precise treatment

中图分类号: 

相关文章

[1] 安天棋, 田建辉, 周奕阳, 罗斌, 阙祖俊, 刘瑶, 于盼, 赵瑞华, 杨蕴. 免疫检查点抑制剂治疗相关胸腔积液的研究进展[J]. 中国癌症杂志, 2025, 35(3): 333-338.
[2] 卢愚风, 王晗, 谢亦璠, 江一舟, 邵志敏. 中国乳腺癌重要基础转化研究——进展与展望[J]. 中国癌症杂志, 2025, 35(2): 143-153.
[3] 曾成, 王沅怡, 王佳妮, 马飞. 乳腺癌免疫检查点抑制剂治疗的研究进展与探索方向[J]. 中国癌症杂志, 2025, 35(2): 195-204.
[4] 肖毅, 吴名, 姚刚. 肿瘤类器官研究现状与展望[J]. 中国癌症杂志, 2024, 34(8): 763-776.
[5] 梁滢昀, 陈健华. 溶瘤病毒联合免疫治疗在恶性肿瘤治疗中的应用进展[J]. 中国癌症杂志, 2024, 34(7): 686-694.
[6] 陈虹, 曹治云. 人源胰腺癌类器官模型的构建及应用新进展[J]. 中国癌症杂志, 2024, 34(6): 590-597.
[7] 陈虹宇, 苏鹏宇, 罗文姿, 庞得全, 王斐然. 放疗中心脏照射剂量体积与自主神经功能紊乱关系的研究[J]. 中国癌症杂志, 2024, 34(11): 1036-1044.
[8] 蒋媛媛, 魏文斐, 吴靖雅, 黎华文. 类器官在妇科恶性肿瘤药物筛选中的应用[J]. 中国癌症杂志, 2024, 34(11): 1053-1060.
[9] 杨梓怡, 顾丙新, 许晓平, 宋少莉. 18F-FDG和68Ga-FAPI PET/CT在不同恶性肿瘤肺转移诊断中的对比研究[J]. 中国癌症杂志, 2023, 33(9): 829-833.
[10] 孙崇源, 赵东兵. 循环肿瘤DNA在胃癌诊疗中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 782-789.
[11] 中国临床肿瘤学会免疫治疗专家委员会, 上海市抗癌协会肿瘤生物治疗专业委员会. 基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识(2022年版)[J]. 中国癌症杂志, 2023, 33(5): 527-548.
[12] 陈祝俊, 丁志敏, 马晓路, 王砚春, 胡昊昀, 卢仁泉, 郭林. 恶性肿瘤患者血流感染病原分析及血糖检测的临床意义[J]. 中国癌症杂志, 2023, 33(10): 927-935.
[13] 中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33(10): 954-967.
[14] 肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[15] 张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022, 32(8): 688-697.